MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.23M | -2.03M | -1.89M | -2.68M | -2.05M |
| Total Depreciation and Amortization | 400.80K | 379.80K | 534.20K | 586.00K | 527.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -516.50K | 525.00K | 600.00K | 568.90K | 314.60K |
| Change in Net Operating Assets | 586.50K | 643.70K | -420.20K | 391.60K | 2.29M |
| Cash from Operations | -762.20K | -485.40K | -1.17M | -1.13M | 1.08M |
| Capital Expenditure | -31.40K | -24.20K | -40.90K | -15.60K | -87.50K |
| Sale of Property, Plant, and Equipment | 0.00 | -- | 15.30K | 405.00K | 130.80K |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | 3.12M |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -31.40K | -24.20K | -25.60K | 389.40K | 3.17M |
| Total Debt Issued | 0.00 | 50.00K | 749.00K | -- | 0.00 |
| Total Debt Repaid | -337.00K | -2.29M | -153.00K | -269.00K | -391.00K |
| Issuance of Common Stock | 14.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 79.00K | 20.00K | 89.00K | 203.00K | 150.00K |
| Cash from Financing | -174.30K | -1.63M | 500.60K | -49.00K | -177.10K |
| Foreign Exchange rate Adjustments | -33.60K | 13.20K | 15.30K | 8.90K | -374.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.00M | -2.13M | -683.30K | -782.50K | 3.70M |